Jubilant Life Sciences divested its entire stake in Safe Foods Corporation, consisting of 5,40,463 shares

Jubilant Life Sciences divests 10% in Safe Foods Corp for Rs 134 cr

Jubilant Ingrevia rallied 3.47% to Rs 786.50 after its wholly owned subsidiary, Jubilant Life Sciences International, Singapore divested its entire 10% stake from Safe Foods Corporation for $18.2 million (approx. Rs 134.20 crore).

Jubilant Ingrevia spurts after its Singaporean arm offloads 10% stake of Safe Foods Corp.

Jubilant Ingrevia on Wednesday said its subsidiary Jubilant Life Sciences International Pte Ltd has divested its 10 per cent stake in Safe Foods Corporation for a consideration of $18.2 million

Jubilant Ingrevia arm divests 10% stake in Safe Foods Corp for $18.2 mn

Salisbury-based Jubilant Cadista Pharmaceuticals Inc is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of Noida-based Jubilant Life Sciences.

Drug makers Granules India, Jubilant Cadista recall products in US market

Jubilant Cadista is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences Company.

Drug firms Granules India, Jubilant Cadista recall products in US market

Anurag Roy has over 21 years’ experience working in leading pharmaceuticals/chemicals Companies such as DSM, Dr. Reddy’s Labs, BASF and Jubilant Life Sciences.

Anurag Roy joins Astec Lifesciences board panel as CEO; Stock dives 4%

Anurag Roy joins Astec Lifesciences as CEO and Whole-time Director; Stock dives 4%

During the second wave of COVID-19, stocks of pharmaceutical, oxygen and other companies involved in tackling COVID-19 have been in focus. But today, there may be some pharmaceutical stocks that may draw more attention of investors.Given is the list of stocks:

Stocks to watch out: Cipla, Jubilant Life Sciences, Godrej Consumer Products, Siemens, Dr Reddy’s among others

Companies like Cipla, Mylan, Jubilant Life Sciences, Hetero Drugs, Syngene International and Dr Reddy’s Laboratories are also manufacturing Remdesivir for the Indian market.

As Covid cases rise, Zydus to scale up Remdesivir production

Jubilant Life Sciences consolidated net profit rises 52.39% in the December 2020 quarter

Jubilant Pharmova (erstwhile Jubilant Life Sciences) hit an upper circuit of 5% at Rs 954.45 after the company reported 52% jump in net profit to Rs 310 crore on a 15% rise in revenue from operations to Rs 2,664 crore in Q3 FY21 over Q3 FY20.

Jubilant Pharmova spurts after recording 52% YoY growth in Q3 PAT

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Jubilant Life Sciences Limited is a pharmaceutical and life sciences company.